{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:51:58Z","timestamp":1792511518433,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H04805"],"award-info":[{"award-number":["21H04805"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004721","name":"The University of Tokyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Fluid retention presenting as effusions in body cavities is sometimes encountered following allogeneic stem cell transplantation (allo-HSCT). It is unclear whether cavity effusions at independent sites may serve as cumulative correlates of fluid overload and whether a higher number of effusion sites are associated with a worse prognosis. Here, we comprehensively reviewed pleural, peritoneal, and pericardial effusions in 178 first allo-HSCT recipients retrospectively. A total of 123 (69.1%) patients developed effusions in any cavity. New pleural, peritoneal, and pericardial effusions were found after allo-HSCT in 106, 88, and 53 patients, at a median of 38.0 (range, 2\u20132950), 22.5 (range, 2\u20131324), and 40 (range, 2\u2013945) days, respectively. The cumulative incidence at day 100 was 41.0%, 40.4%, and 20.8%, respectively. Of the 92 patients who presented with effusions by day 100, 28 patients presented with effusion in a single cavity, 39 in two cavities, and 25 in all three cavities. The 2-year overall survival rates of patients with effusions in zero, one, two, and three cavities by day 100 were 86.1%, 60.0%, 59.6%, and 18.8%, respectively, showing an additive adverse association with outcome. Prospective studies to further characterize fluid dynamics following allo-HSCT are warranted.<\/jats:p>","DOI":"10.1007\/s12185-025-03949-7","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T16:08:01Z","timestamp":1741018081000},"page":"833-847","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic impact of effusion in multiple body cavities after allogeneic hematopoietic stem cell transplantation"],"prefix":"10.1007","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8404-3208","authenticated-orcid":false,"given":"Yasutaka","family":"Masuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Masamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4034-2422","authenticated-orcid":false,"given":"Mineo","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"issue":"22","key":"3949_CR1","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","volume":"363","author":"TA Gooley","year":"2010","unstructured":"Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22):2091\u2013101. https:\/\/doi.org\/10.1056\/NEJMoa1004383.","journal-title":"N Engl J Med"},{"issue":"4","key":"3949_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.7326\/m19-2936","volume":"172","author":"GB McDonald","year":"2020","unstructured":"McDonald GB, Sandmaier BM, Mielcarek M, Sorror M, Pergam SA, Cheng GS, et al. Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003\u20132007 versus 2013\u20132017 cohorts. Ann Intern Med. 2020;172(4):229\u201339. https:\/\/doi.org\/10.7326\/m19-2936.","journal-title":"Ann Intern Med"},{"issue":"24","key":"3949_CR3","doi-asserted-by":"publisher","first-page":"6283","DOI":"10.1182\/bloodadvances.2020003418","volume":"4","author":"O Penack","year":"2020","unstructured":"Penack O, Peczynski C, Mohty M, Yakoub-Agha I, Styczynski J, Montoto S, et al. How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT. Blood Adv. 2020;4(24):6283\u201390. https:\/\/doi.org\/10.1182\/bloodadvances.2020003418.","journal-title":"Blood Adv"},{"issue":"9","key":"3949_CR4","doi-asserted-by":"publisher","first-page":"E341","DOI":"10.1002\/ajh.24435","volume":"91","author":"D Modi","year":"2016","unstructured":"Modi D, Jang H, Kim S, Deol A, Ayash L, Bhutani D, et al. Incidence, etiology, and outcome of pleural effusions in allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2016;91(9):E341\u20137. https:\/\/doi.org\/10.1002\/ajh.24435.","journal-title":"Am J Hematol"},{"issue":"11","key":"3949_CR5","doi-asserted-by":"publisher","first-page":"949.e1","DOI":"10.1016\/j.jtct.2021.07.024","volume":"27","author":"H Kubo","year":"2021","unstructured":"Kubo H, Imataki O, Fukumoto T, Oku M, Ishida T, Kubo YH, et al. Risk factors for and the prognostic impact of pericardial effusion after allogeneic hematopoietic stem cell transplantation. Transplant Cell Ther. 2021;27(11):949.e1-949.e8. https:\/\/doi.org\/10.1016\/j.jtct.2021.07.024.","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"3949_CR6","doi-asserted-by":"publisher","first-page":"13005","DOI":"10.1038\/s41598-023-39604-6","volume":"13","author":"H Kubo","year":"2023","unstructured":"Kubo H, Imataki O, Fukumoto T, Kawanaka Y, Ishida T, Kubo YH, et al. Potential factors for and the prognostic impact of ascites after allogeneic hematopoietic stem cell transplantation. Sci Rep. 2023;13(1):13005. https:\/\/doi.org\/10.1038\/s41598-023-39604-6.","journal-title":"Sci Rep"},{"issue":"5","key":"3949_CR7","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/bjh.13357","volume":"169","author":"YC Liu","year":"2015","unstructured":"Liu YC, Chien SH, Fan NW, Hu MH, Gau JP, Liu CJ, et al. Risk factors for pericardial effusion in adult patients receiving allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2015;169(5):737\u201345. https:\/\/doi.org\/10.1111\/bjh.13357.","journal-title":"Br J Haematol"},{"issue":"2","key":"3949_CR8","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/bmt.2015.227","volume":"51","author":"X Chen","year":"2016","unstructured":"Chen X, Zou Q, Yin J, Wang C, Xu J, Wei J, et al. Pericardial effusion post transplantation predicts inferior overall survival following allo-hematopoietic stem cell transplant. Bone Marrow Transplant. 2016;51(2):303\u20136. https:\/\/doi.org\/10.1038\/bmt.2015.227.","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"3949_CR9","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1378\/chest.12-1292","volume":"143","author":"MP Moy","year":"2013","unstructured":"Moy MP, Levsky JM, Berko NS, Godelman A, Jain VR, Haramati LB. A new, simple method for estimating pleural effusion size on CT scans. Chest. 2013;143(4):1054\u20139. https:\/\/doi.org\/10.1378\/chest.12-1292.","journal-title":"Chest"},{"issue":"23","key":"3949_CR10","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","volume":"123","author":"P Armand","year":"2014","unstructured":"Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123(23):3664\u201371. https:\/\/doi.org\/10.1182\/blood-2014-01-552984.","journal-title":"Blood"},{"issue":"12","key":"3949_CR11","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628\u201333. https:\/\/doi.org\/10.1016\/j.bbmt.2009.07.004.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"3949_CR12","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","volume":"15","author":"S Giralt","year":"2009","unstructured":"Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15(3):367\u20139. https:\/\/doi.org\/10.1016\/j.bbmt.2008.12.497.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"3949_CR13","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912\u20139. https:\/\/doi.org\/10.1182\/blood-2005-05-2004.","journal-title":"Blood"},{"issue":"6","key":"3949_CR14","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649\u201355.","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"3949_CR15","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"3949_CR16","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","volume":"53","author":"HM Schoemans","year":"2018","unstructured":"Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR, et al. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant. 2018;53(11):1401\u201315. https:\/\/doi.org\/10.1038\/s41409-018-0204-7.","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"3949_CR17","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.bbmt.2005.06.001","volume":"11","author":"VT Ho","year":"2005","unstructured":"Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M, et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11(8):571\u20135. https:\/\/doi.org\/10.1016\/j.bbmt.2005.06.001.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"3949_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3324\/haematol.10699","volume":"92","author":"T Ruutu","year":"2007","unstructured":"Ruutu T, Barosi G, Benjamin RJ, Clark RE, George JN, Gratwohl A, et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica. 2007;92(1):95\u2013100. https:\/\/doi.org\/10.3324\/haematol.10699.","journal-title":"Haematologica"},{"issue":"6","key":"3949_CR19","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","volume":"44","author":"RJ Jones","year":"1987","unstructured":"Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation. 1987;44(6):778\u201383. https:\/\/doi.org\/10.1097\/00007890-198712000-00011.","journal-title":"Transplantation"},{"issue":"7","key":"3949_CR20","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/bmt.2016.130","volume":"51","author":"M Mohty","year":"2016","unstructured":"Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016;51(7):906\u201312. https:\/\/doi.org\/10.1038\/bmt.2016.130.","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"3949_CR21","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1038\/bmt.2009.337","volume":"45","author":"Y Kanda","year":"2010","unstructured":"Kanda Y, Yamashita T, Mori T, Ito T, Tajika K, Mori S, et al. A randomized controlled trial of plasma real-time PCR and antigenemia assay for monitoring CMV infection after unrelated BMT. Bone Marrow Transplant. 2010;45(8):1325\u201332. https:\/\/doi.org\/10.1038\/bmt.2009.337.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"3949_CR22","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41409-019-0703-1","volume":"55","author":"T Luft","year":"2020","unstructured":"Luft T, Benner A, Terzer T, Jodele S, Dandoy CE, Storb R, et al. EASIX and mortality after allogeneic stem cell transplantation. Bone Marrow Transplant. 2020;55(3):553\u201361. https:\/\/doi.org\/10.1038\/s41409-019-0703-1.","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"3949_CR23","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o","volume":"18","author":"TA Gooley","year":"1999","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695\u2013706. https:\/\/doi.org\/10.1002\/(sici)1097-0258(19990330)18:6%3c695::aid-sim60%3e3.0.co;2-o.","journal-title":"Stat Med"},{"issue":"3","key":"3949_CR24","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"3949_CR25","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1038\/bmt.2010.297","volume":"46","author":"M Norkin","year":"2011","unstructured":"Norkin M, Ratanatharathorn V, Ayash L, Abidi MH, Al-Kadhimi Z, Lum LG, et al. Large pericardial effusion as a complication in adults undergoing SCT. Bone Marrow Transplant. 2011;46(10):1353\u20136. https:\/\/doi.org\/10.1038\/bmt.2010.297.","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"3949_CR26","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1016\/j.bbmt.2017.08.021","volume":"23","author":"G Rond\u00f3n","year":"2017","unstructured":"Rond\u00f3n G, Saliba RM, Chen J, Ledesma C, Alousi AM, Oran B, et al. Impact of fluid overload as new toxicity category on hematopoietic stem cell transplantation outcomes. Biol Blood Marrow Transplant. 2017;23(12):2166\u201371. https:\/\/doi.org\/10.1016\/j.bbmt.2017.08.021.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"3949_CR27","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12882-016-0323-6","volume":"17","author":"R Claure-Del Granado","year":"2016","unstructured":"Claure-Del Granado R, Mehta RL. Fluid overload in the ICU: evaluation and management. BMC Nephrol. 2016;17(1):109. https:\/\/doi.org\/10.1186\/s12882-016-0323-6.","journal-title":"BMC Nephrol"},{"key":"3949_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102646","volume":"121","author":"JM Berger","year":"2023","unstructured":"Berger JM, Preusser M, Berghoff AS, Bergen ES. Malignant ascites: current therapy options and treatment prospects. Cancer Treat Rev. 2023;121: 102646. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102646.","journal-title":"Cancer Treat Rev"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03949-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-03949-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03949-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T11:32:32Z","timestamp":1748259152000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-03949-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3949"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-03949-7","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"assertion":[{"value":"14 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M. Yosuke received research funding from Kyowa Kirin and lecture fees from AbbVie, Sanofi, Nihon Shinyaku, and Janssen Pharmaceutical. M.K. received research funding from Kyowa Kirin and AbbVie and lecture fees from AstraZeneca and AbbVie. M.K. is an associate editor of International Journal of Hematology. None of these are related to the current study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Consent to publish the study was obtained from the cases.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}